Back to mobile site

Protara Therapeutics (TARA) Reiterated at Overweight by Cantor Fitzgerald After Management Meet

October 15, 2026 7:54 AM EDT Send to a Friend
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Protara Therapeutics (NASDAQ: TARA).The analyst commented, "We hosted Protara management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login